Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Research output: Contribution to journalJournal articlepeer-review

DOI

  1. Restriction of Intravenous Fluid in ICU Patients with Septic Shock

    Research output: Contribution to journalJournal articlepeer-review

  2. Tranexamic Acid in Patients Undergoing Noncardiac Surgery

    Research output: Contribution to journalJournal articlepeer-review

  3. CT or Invasive Coronary Angiography in Stable Chest Pain

    Research output: Contribution to journalJournal articlepeer-review

  4. Acute Achilles' Tendon Rupture - Surgery or No Surgery

    Research output: Contribution to journalEditorialpeer-review

  5. Mitapivat versus Placebo for Pyruvate Kinase Deficiency

    Research output: Contribution to journalJournal articlepeer-review

View graph of relations

BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking antibody, has been shown to be safe and to have antitumor activity in patients with previously treated melanoma, but the safety and activity in patients with previously untreated melanoma need investigation.

METHODS: In this phase 2-3, global, double-blind, randomized trial, we evaluated relatlimab and nivolumab as a fixed-dose combination as compared with nivolumab alone when administered intravenously every 4 weeks to patients with previously untreated metastatic or unresectable melanoma. The primary end point was progression-free survival as assessed by blinded independent central review.

RESULTS: The median progression-free survival was 10.1 months (95% confidence interval [CI], 6.4 to 15.7) with relatlimab-nivolumab as compared with 4.6 months (95% CI, 3.4 to 5.6) with nivolumab (hazard ratio for progression or death, 0.75 [95% CI, 0.62 to 0.92]; P = 0.006 by the log-rank test). Progression-free survival at 12 months was 47.7% (95% CI, 41.8 to 53.2) with relatlimab-nivolumab as compared with 36.0% (95% CI, 30.5 to 41.6) with nivolumab. Progression-free survival across key subgroups favored relatlimab-nivolumab over nivolumab. Grade 3 or 4 treatment-related adverse events occurred in 18.9% of patients in the relatlimab-nivolumab group and in 9.7% of patients in the nivolumab group.

CONCLUSIONS: The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to progression-free survival than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. Relatlimab and nivolumab in combination showed no new safety signals. (Funded by Bristol Myers Squibb; RELATIVITY-047 ClinicalTrials.gov number, NCT03470922.).

Original languageEnglish
JournalThe New England journal of medicine
Volume386
Issue number1
Pages (from-to)24-34
Number of pages11
ISSN0028-4793
DOIs
Publication statusPublished - 6 Jan 2022

Bibliographical note

Copyright © 2022 Massachusetts Medical Society.

    Research areas

  • Adult, Aged, Aged, 80 and over, Antigens, CD/metabolism, Antineoplastic Combined Chemotherapy Protocols/adverse effects, B7-H1 Antigen/antagonists & inhibitors, Double-Blind Method, Female, Humans, Immune Checkpoint Inhibitors/adverse effects, Male, Melanoma/drug therapy, Middle Aged, Nivolumab/adverse effects, Progression-Free Survival

ID: 72728833